Niclosamide ethanolamine improves blood glycemic control and reduces hepatic steatosis in mice

[1]  Michael J. MacDonald,et al.  Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase , 2014, Nature.

[2]  G. Shulman,et al.  Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler. , 2013, Cell metabolism.

[3]  S. Summers,et al.  A ceramide-centric view of insulin resistance. , 2012, Cell metabolism.

[4]  G. Shulman,et al.  Mechanisms for Insulin Resistance: Common Threads and Missing Links , 2012, Cell.

[5]  Paul Shekelle,et al.  Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians , 2012, Annals of Internal Medicine.

[6]  D. Scudiero,et al.  Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer. , 2011, Journal of the National Cancer Institute.

[7]  Wei Chen,et al.  Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. , 2011, Cancer research.

[8]  D. Williamson,et al.  Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence , 2010, Population health metrics.

[9]  Qiang He,et al.  Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. , 2010, ACS medicinal chemistry letters.

[10]  K. Petersen,et al.  Lipid-induced insulin resistance: unravelling the mechanism , 2010, The Lancet.

[11]  Y. Tseng,et al.  Cellular bioenergetics as a target for obesity therapy , 2010, Nature Reviews Drug Discovery.

[12]  M. Komatsu,et al.  Adipose-specific deletion of autophagy-related gene 7 (atg7) in mice reveals a role in adipogenesis , 2009, Proceedings of the National Academy of Sciences.

[13]  X. Ren,et al.  The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. , 2009, Biochemistry.

[14]  Kyongbum Lee,et al.  Metabolic Flux Analysis of Mitochondrial Uncoupling in 3T3-L1 Adipocytes , 2009, PloS one.

[15]  D. Nathan.  Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2009, Diabetes Care.

[16]  F. Schick,et al.  High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease , 2008, Gut.

[17]  M. Brand,et al.  The efficiency of cellular energy transduction and its implications for obesity. , 2008, Annual review of nutrition.

[18]  A. Schürmann,et al.  Uncoupling protein 1 expression in murine skeletal muscle increases AMPK activation, glucose turnover, and insulin sensitivity in vivo. , 2008, Physiological genomics.

[19]  G. Shulman,et al.  Overexpression of uncoupling protein 3 in skeletal muscle protects against fat-induced insulin resistance. , 2007, The Journal of clinical investigation.

[20]  M. Birnbaum,et al.  Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. , 2007, Cell metabolism.

[21]  L. Scorrano,et al.  Organelle isolation: functional mitochondria from mouse liver, muscle and cultured filroblasts , 2007, Nature Protocols.

[22]  M. Kushmerick,et al.  Mild mitochondrial uncoupling impacts cellular aging in human muscles in vivo , 2007, Proceedings of the National Academy of Sciences.

[23]  S. Kahn,et al.  Mechanisms linking obesity to insulin resistance and type 2 diabetes , 2006, Nature.

[24]  C. Newgard,et al.  Obesity-related derangements in metabolic regulation. , 2006, Annual review of biochemistry.

[25]  L. Kozak,et al.  Uncoupling proteins: current status and therapeutic prospects , 2005, EMBO reports.

[26]  Nimesh Mody,et al.  Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes , 2005, Nature.

[27]  K. Petersen,et al.  Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. , 2005, Diabetes.

[28]  T. Asano,et al.  Dissipating excess energy stored in the liver is a potential treatment strategy for diabetes associated with obesity. , 2005, Diabetes.

[29]  W. Maragos,et al.  Mitochondrial uncoupling as a potential therapeutic target in acute central nervous system injury , 2004, Journal of neurochemistry.

[30]  D. Befroy,et al.  Mechanism of Hepatic Insulin Resistance in Non-alcoholic Fatty Liver Disease* , 2004, Journal of Biological Chemistry.

[31]  G. Cline,et al.  Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. , 2004, Diabetes.

[32]  David Millington,et al.  Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance , 2004, Nature Medicine.

[33]  K. Inoki,et al.  TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival , 2003, Cell.

[34]  G. Tomasevic,et al.  Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma , 2003, Nature Medicine.

[35]  G. Shulman,et al.  Mechanism by Which Fatty Acids Inhibit Insulin Activation of Insulin Receptor Substrate-1 (IRS-1)-associated Phosphatidylinositol 3-Kinase Activity in Muscle* , 2002, The Journal of Biological Chemistry.

[36]  David Carling,et al.  The Anti-diabetic Drugs Rosiglitazone and Metformin Stimulate AMP-activated Protein Kinase through Distinct Signaling Pathways* , 2002, The Journal of Biological Chemistry.

[37]  M. Brand,et al.  Mitochondrial uncoupling as a target for drug development for the treatment of obesity , 2001, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[38]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[39]  Michael Karin,et al.  Reversal of Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of Ikkβ , 2001, Science.

[40]  Y. Terauchi,et al.  The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity , 2001, Nature Medicine.

[41]  M. Lazar,et al.  The hormone resistin links obesity to diabetes , 2001, Nature.

[42]  J. Ju,et al.  Skeletal muscle respiratory uncoupling prevents diet-induced obesity and insulin resistance in mice , 2000, Nature Medicine.

[43]  Martin D. Brand,et al.  Mice overexpressing human uncoupling protein-3 in skeletal muscle are hyperphagic and lean , 2000, Nature.

[44]  M. Owen,et al.  Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. , 2000, The Biochemical journal.

[45]  G. Swan.  The pharmacology of halogenated salicylanilides and their anthelmintic use in animals. , 1999, Journal of the South African Veterinary Association.

[46]  G. Shulman,et al.  Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. , 1999, Diabetes.

[47]  R. Coleman,et al.  AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. , 1999, The Biochemical journal.

[48]  P. J. Randle,et al.  Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. , 1998, Diabetes/metabolism reviews.

[49]  G. A. Fleming,et al.  Lactic acidosis in patients with diabetes treated with metformin. , 1998, The New England journal of medicine.

[50]  J. D. Smyth,et al.  The mechanisms of action of antiprotozoal and anthelmintic drugs in man. , 1997, General pharmacology.

[51]  D L Rothman,et al.  Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. , 1996, The New England journal of medicine.

[52]  B. Spiegelman,et al.  Expression of the mitochondrial uncoupling protein gene from the aP2 gene promoter prevents genetic obesity. , 1995, The Journal of clinical investigation.

[53]  M. Pelleymounter,et al.  Effects of the obese gene product on body weight regulation in ob/ob mice. , 1995, Science.

[54]  J. Olefsky,et al.  Effects of Weight Loss on Mechanisms of Hyperglycemia in Obese Non-Insulin-Dependent Diabetes Mellitus , 1986, Diabetes.

[55]  J. Parascandola.  Dinitrophenol and bioenergetics: An historical perspective , 1974, Molecular and Cellular Biochemistry.

[56]  E. C. Weinbach,et al.  Mechanism of Action of Reagents that uncouple Oxidative Phosphorylation , 1969, Nature.

[57]  Yifan Zhang,et al.  Oxidative metabolism: glucose versus ketones. , 2013, Advances in experimental medicine and biology.

[58]  Robert I. Krieger,et al.  HANDBOOK OF PESTICIDE TOXICOLOGY , 2001 .

[59]  L. Chan,et al.  The db/db mouse, a model for diabetic dyslipidemia: molecular characterization and effects of Western diet feeding. , 2000, Metabolism: clinical and experimental.

[60]  K. Uysal,et al.  Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. , 1997, Nature.

[61]  D. Wallace,et al.  Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. , 1996, Methods in enzymology.

[62]  M. Maffei,et al.  Positional cloning of the mouse obese gene and its human homologue , 1995, Nature.

[63]  P. Andrews,et al.  The biology and toxicology of molluscicides, Bayluscide. , 1982, Pharmacology & therapeutics.

[64]  P. Heytler.  Uncouplers of oxidative phosphorylation. , 1980, Pharmacology & therapeutics.

[65]  U. Sheth.  Mechanisms of anthelmintic action. , 1975, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.